Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Clinical trial NCT02261714 · COMPLETED

Trial details

NCT number: NCT02261714
Sponsor: Targovax ASA
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer, Resected

Start date: 2012-12-01
Primary completion: 2019-05-01
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.